Page 22 - Company Codes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Commercial launch anticipated in Summer 2021 - MISSISSAUGA, ON, March 1, 2021 /PRNewswire/ -Nuvo Pharmaceuticals Inc.. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that its wholly owned subsidiary, Nuvo Pharmaceuticals (Ireland) DAC trading as Miravo Healthcare (Miravo Ireland), has entered into an exclusive license and supply agreement (the License Agreement) with  The Mentholatum Company, Inc. for the exclusive right to commercialize t...

  PRINCETON, N.J., Feb. 1, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Hong Kong Registrar of Patents has granted a patent for the application titled "Formulations and Methods of Treatment of Skin Conditions" (No. 16102842.8), published on January 29, 2021 under Publication No. 1214771 B.  The granted claims are directed to the therapeutic use of synthetic hypericin in the treatment...

Published: Jan 26, 2021   NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Q Biomed Inc. (OTCQB: QBIO), announces that it has received additional notices of patent allowances from both Canada and Japan for its Uttroside-B molecule intended to treat liver cancer. The patent titled "Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma" is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. International and additional U.S. claims are currently under prosecution for the tech...

Published: Jan 21, 2021 The FDA Is In The Process Of Investigation And Conducting Their Due Diligence For Efficacy And Safety Patented Polarization Technology Brings Increased Effectiveness in Venom-To-Drug Development BURBANK, Calif., Jan. 21, 2021 /PRNewswire/ -- Medolife Rx, Inc., ("Medolife") the majority owner of Quanta, Inc. (OTCPK: QNTA) today announced that Medolife and The Ministry of Environment of The Dominican Republic signed an exclusive 10-year agreement with automatic renewal. This groundbreaking partnership encompasses exclusive rights for investigations, production, and...

Published: Jan 21, 2021   LAVAL, QC, Jan. 21, 2021 /PRNewswire/ -- Bausch & Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that LUMIFY ® (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops have received approval from the Ministry of Food and Drug Safety (MFDS) in South Korea. "The approval of LUMIFY in South Korea marks another step in our global rollout of these innovative redness reliever eye drops," said Thomas J. Appio, president, Bausch + Lomb/International. "LUMIFY will be a we...